From: High HSPB1 expression predicts poor clinical outcomes and correlates with breast cancer metastasis
Characteristics | Total(N) | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
Age | 1082 | Â | Â | Â | Â |
<  = 60 | 601 | Reference |  |  |  |
> 60 | 481 | 2.020 (1.465–2.784) |  < 0.001 | 3.430 (1.821–6.460) |  < 0.001 |
T stage | 1079 | Â | Â | Â | Â |
T1 | 276 | Reference | Â | Â | Â |
T2&T3&T4 | 803 | 1.482 (1.007–2.182) | 0.046 | 1.014 (0.371–2.776) | 0.978 |
N stage | 1063 | Â | Â | Â | Â |
N0 | 514 | Reference | Â | Â | Â |
N1&N2&N3 | 549 | 2.239 (1.567–3.199) |  < 0.001 | 1.878 (0.885–3.985) | 0.101 |
M stage | 922 | Â | Â | Â | Â |
M0 | 902 | Reference | Â | Â | Â |
M1 | 20 | 4.254 (2.468–7.334) |  < 0.001 | 5.195 (1.718–15.708) | 0.004 |
Pathologic stage | 1059 | Â | Â | Â | Â |
Stage I | 180 | Reference | Â | Â | Â |
Stage II&Stage III&Stage IV | 879 | 2.210 (1.313–3.721) | 0.003 | 2.120 (0.473–9.507) | 0.326 |
ER status | 1032 | Â | Â | Â | Â |
Negative | 240 | Reference | Â | Â | Â |
Positive | 792 | 0.712 (0.495–1.023) | 0.066 | 0.572 (0.229–1.425) | 0.230 |
PR status | 1029 | Â | Â | Â | Â |
Negative | 342 | Reference | Â | Â | Â |
Positive | 687 | 0.732 (0.523–1.024) | 0.068 | 0.728 (0.309–1.716) | 0.468 |
HER2 status | 715 | Â | Â | Â | Â |
Negative | 558 | Reference | Â | Â | Â |
Positive | 157 | 1.593 (0.973–2.609) | 0.064 | 0.678 (0.317–1.450) | 0.316 |
radiation_therapy | 986 | Â | Â | Â | Â |
No | 434 | Reference | Â | Â | Â |
Yes | 552 | 0.576 (0.394–0.841) | 0.004 | 0.653 (0.354–1.203) | 0.172 |
HSPB1 | 1082 | Â | Â | Â | Â |
Low | 541 | Reference | Â | Â | Â |
High | 541 | 1.208 (1.074–1.455) | 0.037 |  |  |